Contemporary Concise Review 2019: Interstitial lung disease

Abstract

Antifibrotic therapy has been proven to be effective in the treatment of progressive fibrosing lung diseases other than IPF.• The COLDICE study has demonstrated that transbronchial lung cryobiopsy (TBLC) is an important diagnostic technique with good concordance when compared with surgical lung biopsy (SLB). • Telomere dysfunction is associated with progressive fibrosis and a poor prognosis in a broad range of ILDs such as IPF, chronic hypersensitivity pneumonitis and autoimmune-related ILD. • In IPF, large genome-wide association studies have confirmed the importance of the MUC5B promotor variant rs35705950 amongst other novel genetic loci. • A randomized controlled trial of thrombomodulin for treatment of acute exacerbations of IPF was negative-this proves that trials of this devastating complication of IPF are feasible and required.

Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway

“…This minor allele was present at a frequency of 38% in patients with IPF. The odds ratios for disease among patients who were heterozygous and those who were homozygous for the minor allele of this SNP were 9.0 (95% CI: 6.2–13.1) and 21.8 (95% CI: 5.1–93.5), respectively [ 45 ]. However, these genetic mutations do not induce pulmonary fibrosis directly in mouse models [ 11 ].…”

Estudo fitoquímico das folhas e galhos de Endlicheria paniculata e avaliação das atividades biológicas dos extratos e neolignanas

“…Isso poderia levar a mudanças estruturais e funcionais em diferentes órgãos, resultando em danos à saúde do indivíduo (WICK et al, 2013;WEISKIRCHEN, WEISKIRCHEN, TACKE, 2019), como visto na cirrose hepática, doença renal crônica e doença pulmonar (SAFFIOTI, PINZANI, 2016;HUMPHREYS, 2018;GEORGE, WELLS, 2020).…”